PEOPLE ON THE MOVE
Actinium
Immunotherapy company Actinium has made ex-Bristol-Myers Squibb Felix Garzon senior VP and head of clinical development.
"Felix's deep expertise in hematology and oncology drug development will strengthen the Actinium team,” said CEO Kaushik Dave. The company is preparing for trials of its combination mAb and radiopharmaceutical drugs Iomab-B for bone marrow transplant patients, and Actimab-A for acute myelogenous leukemia.
Garzon was previously senior director of oncology product creation at Eisai and director of global oncology clinical research at Bristol-Myers Squibb. He has also worked at Chiron, Cell Therapeutics, Rhône-Poulenc Rorer, Pharmacia & Upjohn and Ipsen.
